Free under $10 Ticker Biotech Quarter Review Tier 1 basket — strategic biotech and specialty pharma - Abeona Therapeutics Inc.

ABEO (quick overview): Abeona’s strategic appeal is ZEVASKYN’s maturity: it is a rare-dermatology and gene-therapy commercial proposition for recessive dystrophic epidermolysis bullosa, not an exploratory discovery program. A partner or acquirer would gain a defined patient population, specialist-treatment channel and global commercialization opportunity, while launch execution, manufacturing, payer access, treatment-center readiness and monetization of ex-U.S. rights remain the principal value drivers and risks.

Read full article (1 min)